Skip to Content
Merck
  • Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors.

Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors.

Journal of oncology (2012-07-14)
Faruk Tas
ABSTRACT

Metastatic melanoma (MM) is a fatal disease with a rapid systemic dissemination. This study was conducted to investigate the metastatic behavior, timing, patterns, survival, and influencing factors in MM. 214 patients with MM were evaluated retrospectively. Distant metastases (82%) were the most frequent for patients initially metastatic. The median and 1-year survival rates of initially MM patients were 10 months and 41%, respectively. The median time to metastasis for patients with localized disease was 28 months. The timing of appearance of metastases varied minimally; however, times to metastases for distant organs varied greatly. For the first metastatic pathway, more than half of the primary metastases were M1A (57%). These findings were in contrast to the results compared with those with metastatic in diagnosis (P < 0.001). The median and 1-year survival rates of all patients were 12 months and 49%, respectively. Outcome was higher in M1A than visceral metastases (P < 0.001). In conclusion, the fact that over half of all recurrences/metastases occurred within 3 years urges us to concentrate follow-up in the early time periods following diagnosis. Because the clinical behavior of MM is variable, the factors for survival consisting of site and number of metastases should be emphasized.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
LOX-IMVI Human Melanoma Cell Line, LOX-IMVI human melanoma cell line is an excellent model for probing mechanisms of metastasis and for evaluation of chemotherapies.